Fig. 1 · Structure

Documents & Downloads

Ivachtin

Cat. No. A15300 CAS 745046-84-8

Caspase-3 inhibitor

Ivachtin is a potent, cell-permeable, reversible, non-competitive inhibitor of Caspase-3 (IC50 = 23 nM).

In Stock

Publications for Ivachtin

1 publication citing this product

  1. Yosefzon Y, .et al. , Mol Cell, 2018, May 17;70(4):573-587.e4 PMID: 29775577

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Ivachtin corresponds to compound 7a, a nonpeptide caspase-3 inhibitor. The original fluorogenic assay reported an IC50 of 23 ± 2 nM; a separate substrate-variation analysis reported 23 ± 6 nM and supported a noncompetitive inhibition pattern. These are assay endpoints, not cellular treatment doses. [1]

The caspase panel showed the greatest potency against caspase-3, with modest selectivity over other caspases. Cellular effects therefore should not be treated as proof of exclusive caspase-3 inhibition. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Caspase-3 IC50 23 nM

In Vitro Studies

In COSAN-exposed HEK293 cells, 100 nM Ivachtin co-treatment reduced blebbing and supported recovery after washout. The experiment tested protection during COSAN exposure and subsequent recovery, rather than Ivachtin monotherapy. [2]

Activity depended on the model and endpoint. In CHO-7W cells, Ivachtin had limited efficacy against cerivastatin-induced APPΔC31 production after 24 h, while Q-VD-OPh strongly reduced the signal. [3]

Caspase-3 potency and substrate-competition characterization

Biochemical assay · Recombinant human caspase-3; Ac-DEVD-AMC fluorogenic substrate [1]

Compound 7a inhibited caspase-3. Substrate variation supported a noncompetitive pattern; reversibility is not adopted.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Caspase-3-catalyzed Ac-DEVD-AMC cleavageIC50 23 ± 2 nM[1]
Caspase-3 inhibition across substrate concentrationsIC50 23 ± 6 nM[1]
Substrate dependence of inhibitionKinetic pattern Noncompetitive pattern: reduced Vmax without an apparent Km shift[1]

Literature-Reported Treatment Conditions

Treatment concentration
0–0.8 μM for mechanistic characterization
Exposure duration
Initial-velocity measurements; assay exposure time not specified
Method
Ac-DEVD-AMC varied from 2–60 μM; standard assay uses 10 μM substrate. Fluorescence excitation/emission 360/460 nm.
Vehicle
5% final DMSO
Reported limits
SI buffer sentence is internally malformed and is not reconstructed. SI explicitly lists 5 mM β-mercaptoethanol. Table and kinetic IC50 uncertainty definitions are not supplied.
Methods and source locations

Compound reported in the paper: Ivachtin; Compound label in the paper: 7a

Applies to the named molecular compound; does not validate any Adooq lot.

p. 3682 Table 1, Figures 1–2; SI S12, S14 Figure S1

Caspase-3-catalyzed Ac-DEVD-AMC cleavage: Fluorescence-rate inhibition assay; SI specifies mean of three independent measurements per experimental point. Meaning of the table ± term is not defined. — p. 3682 Table 1, row 7a; SI S12 Enzyme Inhibition Assay

Caspase-3 inhibition across substrate concentrations: Substrate-variation experiment; reported in text, separate from Table 1 estimate; uncertainty type not defined. — p. 3682 text accompanying Figure 1

Substrate dependence of inhibition: Inhibition curves and initial-velocity substrate curves; Lineweaver–Burk representation. — p. 3682 Figures 1–2 and text; SI S14 Figure S1

Caspase panel limits target specificity

Biochemical assay · Recombinant human caspase panel and enzyme-specific substrates [1]

Caspase-3 was the most strongly inhibited enzyme in the panel, but selectivity over other caspases was modest.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Relative inhibitory potency across caspasesSelectivity Caspase-3 most potent; modest selectivity over remaining caspases[1]

Literature-Reported Treatment Conditions

Treatment concentration
Incremental inhibitor concentrations; exact panel range not specified in Figure S3 caption
Method
Enzyme-specific fluorogenic substrates; time-dependent fluorescence
Vehicle
DMSO per shared enzyme-assay methods
Reported limits
Per-enzyme substrate concentrations and replicate/error definitions not specified for this panel. Main text describes caspases 1–9; SI graphic also labels caspase-10.
Methods and source locations

Compound reported in the paper: Ivachtin; Compound label in the paper: 7a

Applies to the named molecular compound; does not validate any Adooq lot.

p. 3682 selectivity paragraph; SI S12, S15 Figure S3

Relative inhibitory potency across caspases: pIC50 panel from concentration-response measurements of substrate-cleavage fluorescence; no exact bar values inferred. — p. 3682 selectivity paragraph; SI S15 Figure S3 and caption

Ivachtin co-treatment during COSAN exposure

Cell-based study · Low-density human HEK293 cells exposed to COSAN [2]

Ivachtin co-treatment reduced the blebbing morphology associated with COSAN exposure and supported cell recovery after washout. This is a combination result, without an Ivachtin-alone comparison.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Morphology at 24 h and cell density after treatment/washoutQualitative rescue Reduced blebbing and recovery of cell density after COSAN plus Ivachtin treatment followed by washout[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM Ivachtin
Exposure duration
24 h co-treatment, then washout and 24 h further growth
Method
Ivachtin plus COSAN exposure followed by removal of both agents
Co-treatment
200 μM COSAN
Reported limits
Ivachtin supplier/form, vehicle and precise low-density plating number not specified in the relevant source passages. Methods list both direct counting and ATP luminescence for mammalian cells without assigning Figure 1D to a single readout.
Methods and source locations

Compound reported in the paper: Ivachtin

Results apply to the paper’s named Ivachtin reagent in the stated model and combination.

Figure 1C–D and caption; Results mammalian-cell paragraphs; Methods cell-number assessment

Morphology at 24 h and cell density after treatment/washout: Phase-contrast images and cell-density endpoint; Figure 1D shows mean ± SD for 3 independent experiments. Exact bar heights not extracted. — Figure 1C–D and caption; Results mammalian-cell paragraph beginning “For some cells and growth conditions”

Limited inhibition of statin-induced APP cleavage

Cell-based study · CHO-7W cells stably expressing human wildtype APP751 [3]

Ivachtin showed limited efficacy against cerivastatin-induced APPΔC31 production under the tested conditions, whereas the pan-caspase control Q-VD-OPh strongly reduced the signal.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cerivastatin-induced APPΔC31 productionQualitative concentration response Limited efficacy of Ivachtin in this model[3]

Literature-Reported Treatment Conditions

Treatment concentration
Increasing Ivachtin concentrations; plotted upper concentration 30 μM
Exposure duration
24 h
Method
Cell co-treatment; APPΔC31 measured by AlphaLISA
Co-treatment
10 μM cerivastatin
Reported limits
Ivachtin supplier/form, final vehicle concentration, and S3B-specific replicate/error semantics are not defined in the examined passages. Do not borrow n from other experiments.
Methods and source locations

Compound reported in the paper: Ivachtin

Results apply to the paper’s named Ivachtin reagent in the stated model and combination.

SI Figure S3B and caption; relevant Results paragraph; Methods AlphaLISA and validation

Cerivastatin-induced APPΔC31 production: AlphaLISA of APPΔC31 in cell lysates; Figure S3B viewed. No IC50 or exact percentage inferred. — Results “Validation of Inhibitors of the C-terminal Cleavage of APP”, paragraph beginning “Since APPΔC31”; SI Figure S3B and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 745046-84-8
Applications Caspase-3 inhibitor
Formula C20H21N3O7S
Molecular Weight 447.46
SMILES
CC1=C2C(=C3C=C(C=CC3=N1)S(=O)(=O)N4CCOCC4)C(=O)N(C2=O)CCOC(=O)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Dmitri V. Kravchenko, Yulia A. Kuzovkova, Volodymyr M. Kysil, et al. Synthesis and structure-activity relationship of 4-substituted 2-(2-acetyloxyethyl)-8-(morpholine-4-sulfonyl)pyrrolo[3,4-c]quinoline-1,3-diones as potent caspase-3 inhibitors Journal of Medicinal Chemistry (2005). PMID: 15916416 DOI: 10.1021/jm048987t Source material
  2. [2] Màrius Tarrés, Elisabetta Canetta, Eleanor Paul, et al. Biological interaction of living cells with COSAN-based synthetic vesicles Scientific Reports (2015). PMID: 25588708 DOI: 10.1038/srep07804 Source material
  3. [3] Karen S. Poksay, Douglas J. Sheffler, Patricia Spilman, et al. Screening for Small Molecule Inhibitors of Statin-Induced APP C-terminal Toxic Fragment Production Frontiers in Pharmacology (2017). PMID: 28261092 DOI: 10.3389/fphar.2017.00046 Source material

Publications

1 publication citing this product

  1. Yosefzon Y, .et al. , Mol Cell, 2018, May 17;70(4):573-587.e4 PMID: 29775577

Added to your cart

View Cart Checkout
Loading...